Anticoagulation in Patients With Venous Thromboembolism and Cancer
NCT ID: NCT04618913
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
1 participants
OBSERVATIONAL
2020-12-14
2026-04-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer
NCT01803022
Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation
NCT02161965
Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
NCT03965741
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
NCT04979780
DOAC - Dosing Options in AntiCoagulation Prophylaxis
NCT07005024
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VTE and history of cancer
VTE and history of cancer
Apixaban
Anticoagulant
Rivaroxaban
Anticoagulant
Edoxaban
Edoxaban
Dabigatran
Dabigatran
VKA
Vitamin K antagonist
LMWH
Low Molecular Weight Heparin
VTE and active cancer
VTE and active cancer
Apixaban
Anticoagulant
Rivaroxaban
Anticoagulant
Edoxaban
Edoxaban
Dabigatran
Dabigatran
VKA
Vitamin K antagonist
LMWH
Low Molecular Weight Heparin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Apixaban
Anticoagulant
Rivaroxaban
Anticoagulant
Edoxaban
Edoxaban
Dabigatran
Dabigatran
VKA
Vitamin K antagonist
LMWH
Low Molecular Weight Heparin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Active cancer or history of cancer
* Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH
* Age ≥ 18 years at the date of index VTE (Venous thromboembolic)
Exclusion Criteria
* Diagnosis of prior atrial fibrillation
* Inferior Vena Cava (IVC) filter
* Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation - note: Prophylactic use of (OAC)/(PAC) allowed.
* Pregnancy
* More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed on the index date.
* Patients with less than one day of follow up
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B0661150
Identifier Type: -
Identifier Source: org_study_id
VICTORIE
Identifier Type: OTHER
Identifier Source: secondary_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.